Search for a trial

A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC).

OBJECTIVE AND HYPOTHESISPrimary ObjectiveThe primary objective is to determine whether abiraterone acetate in combination with low-doseprednisone and androgen deprivation therapy (ADT) is superior to ADT alone in improving rPFS and OS insubjects…

The use of indocyanine green for accurate sentinel node detection and removal in a group of high-risk nodal metastasis prostate cancer patients
To optimize and improve the sentinel node procedure in men with prostate cancer

The overall goal of this study is to further validate and improve the sentinel node procedure for prostate cancer using ICG-99mTc-nanocolloid. The first objective aims at further validation of the sentinel node procedure for prostate cancer via…

Oncolytic adenovirus therapy as an adjuvant treatment for localised prostate cancer.

The main objective is to evaluate the safety and tolerability of Ad[I/PPT-E1A] as an adjuvant treatment for localised prostate cancer before radical prostatectomy. A secondary objective is to explore the histopathological and immunological effects…

Value of multiparametric MR and MRI-guided biopsies of the prostate in men with an elevated PSA

To investigate the additional value of MRI and MRI-guided biopsy in men with an elevated PSA in the general practitioners* (GP) practice regarding the detection of both insignificant and significant cancer, and reduced biopsies.

[18F]-labelled FDHT in PET/CT for detection and staging of bone metastases in hormone naïve prostate cancer

Primary Objective: the primary objective of this study is to determine the feasibility of [18F]FDHT PET/CT for in vivo evaluation of bone metastases in prostate cancer. Active locations will be compared with those seen on conventional imaging (bone…

Clinical trial with Sarabesin 3, a GRP receptor antagonist, labelled with gallium-68, in patients with prostate cancer confined to the primary organ

In this proposed study, we aim to test not only the safety and biodistribution of [68Ga]Sarabesin 3, but also its potential to visualise prostate cancer. If the peptide proves to be successful, a next study will be initiated to test the potential to…

An exploratory, open label, single-arm study to evaluate the effect of Eligard® 6-month on biomarkers of disease in patients with metastatic prostate cancer

To explore the effect of Eligard® on the following prostate cancer biomarkers:• Testosterone in serum• Prostate Specific Antigen (PSA) in serum• Prostate Cancer Antigen (PCA3 score) in urine • PSA mRNA in blood/PBMC• PCA3 mRNA in blood/PBMC• TMPRSS2…

Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis

To provide access to Radium-223 dichloride to patients diagnosed with CRPC/HRPC with bonemetastasis.

MR biopsy versus MR guided ultrasound fusion biopsy in prostate cancer diagnosis

The main objective is to compare the clinical effectiveness of MRgUSBx versus MRgMRBx to provide evidence that MRgUSBx can partly replace MRgMRBx. Secondary objectives are: to determine the actual spatial targeting accuracy to further investigate if…

Prostate cancer Research International: Active Surveillance (PRIAS) MRI study

To study the value of mpMRI with subsequent targeted biopsies after inclusion to more accurately grade prostate cancers of men on active surveillance. Furthermore, the value of mpMRI in reducing the number and amount of biopsies will be studied.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer

This study has been transitioned to CTIS with ID 2023-509221-47-00 check the CTIS register for the current data. To demonstrate superiority in the metastasis-free survival (MFS) of men with high risk NM-CRPC treated with apalutamide versus…

A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapy

The primary objective is to show superiority of treatment with DCVAC/PCa in addition to Standard of Care chemotherapy (docetaxel plus prednisone) over placebo in addition to Standard of Care chemotherapy (docetaxel plus prednisone) in men with mCRPC…